Typhoid fever is caused by Salmonella typhi bacteria that are transmitted through contaminated food and drink in conditions of poor sanitation. Without prompt treatment with antibiotics typhoid fever can cause serious complications and even death. It is estimated in the developing world that typhoid fever affects around 21.5 million persons each year.
Travellers to typhoid endemic countries are recommended to be vaccinated at least two weeks before departure. There are two main typhoid vaccines available: Crucell/J&J's oral Vivotif and Sanofi's Typhim Vi. Typhoid vaccines are not widely used in the public sector in endemic countries.
This MarketVIEW product contains a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of typhoid vaccines in the travelling populations from major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions per product type along with timeframe, pricing and penetration estimates for all target populations. Coverage of commercial typhoid vaccine sales and supply is also included.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%.
Please review the TERMS and CONDITIONS of purchase.
